Proteome Sciences plc announce Good Clinical Laboratory Practice Accreditation
Proteome Sciences are pleased to announce the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will enable the Company to extend its proteomic services to the analysis of clinical trial samples.
Proteome Sciences are a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. They offer various Discovery Services to characterise proteins and their associated post translational modifications. By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, they can detect many thousands of proteins per sample. With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
ELISA kits cover 5% of the human proteome, so there are usually no available assay kits to these disease relevant protein biomarkers. The challenge has been how to convert these novel identified biomarkers into assays fit for use in a clinical trial.
Following identification above, Proteome Sciences can now a develop a targeted SRM Mass Spectrometry based assay which, after validation, can be used for fit-for-purpose biomarker assays in a GCLP certified clinical trial environment. This can be done for one to 50 proteins in a single multiplexed assay.
For further information:
Richard Dennis, Chief Commercial Officer
Tel: +44 (0)20 7043 2116
richard.dennis@proteomics.com
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signaling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibratorTM). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer’s disease, and these are available for license.